The first participants in Pfizer’s new study looking at coadministration of a third dose of the company’s Covid-19 vaccine and a pneumococcal vaccine candidate received their shots Monday, the company said in a press release.
The trial’s primary objective is to look at safety of the vaccines when they are co-administered, as well as follow up six months after vaccination.
The trial will also look at immune responses produced by each vaccine. Pneumococcal vaccines help prevent illnesses caused by Streptococcus pneumoniae bacteria, such as pneumonia.
The trial will include 600 adults over the age of 65, recruited from the company’s large Covid-19 vaccine Phase 3 trial and who received their second Covid-19 vaccine at least six months before entering this study.
Participants will be randomized into three groups: those who receive the pneumococcal conjugate vaccine candidate 20vPnC and a third booster shot of the Covid-19 vaccine; those who receive 20vPnC and a placebo; and those who receive a Covid-19 booster shot and a placebo.
Out of an abundance of caution, the US Centers for Disease Control and Prevention had previously recommended administering Covid-19 vaccines alone.
The agency now says Covid-19 vaccines and other vaccines can be administered without record to timing. “Although data are not available for COVID-19 vaccines administered simultaneously with other vaccines, extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone,” the agency now says.